In the US, Pembrolizumab (pembrolizumab systemic) is a member of the drug class Anti-PD-1 monoclonal antibodies and is used to treat Head and Neck Cancer, Hodgkin's Lymphoma, Melanoma, Melanoma - Metastatic and Non-Small Cell Lung Cancer.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Antineoplastic agent: Monoclonal antibody
Immunoglobulin G4-kappa, anti-[Homo sapiensPDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;Gamma4 heavy chain (1-447) [humanized VH (Homo sapiensIGHV1-2*02 (79.60%) -(IGHD)-IGHJ4*01 L123>T (115)) [8.8.13] (1-120) -Homo sa (WHO)
- Pembrolizumabum (Latin)
- Pembrolizumab (German)
- Pembrolizumab (French)
- Pembrolizumab (Spanish)
- Lambrolizumab (OS: USAN)
- UNII-DPT0O3T46P (IS)
Merck, Canada; Merck, Slovenia; Merck Sharp & Dohme, United Kingdom; Merck Sharp & Dohme, Slovakia; Merck Sharp & Dohme, United States; MSD, Switzerland; MSD France, France
MSD SHARP & DOHME, Germany
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.